Dr. Miri Halperin Wernli is a seasoned global healthcare executive, scientist, and entrepreneur with over three decades of leadership in the life sciences, biotechnology, and pharmaceutical industries. A strategic thinker and inspiring leader, she seamlessly integrates clinical therapeutics with deep expertise in drug and product development within highly regulated environments.Driven by a passion for innovation, Dr. Halperin Wernli excels at transforming cutting-edge discoveries into impactful products and creating business opportunities that benefit both patients and society. She has held senior leadership positions at multinational corporations and has spearheaded pioneering ventures in emerging fields of medicine and mental health. Most recently, she served as Executive President of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for brain health. Previously, she was the Co-Founder, Group CEO, and Executive Board Director of Creso Pharma (ASX:CPH), a leader in medicinal cannabis therapeutics. Her earlier career includes senior global roles at Merck Sharp & Dohme, Roche, and Actelion Pharmaceuticals, where she contributed her expertise across Switzerland and the United States. Her comprehensive knowledge of pharmaceutical and biomedical R&D spans the entire development continuum—ranging from preclinical research to clinical development, regulatory strategies, product registration, and commercial launch—across multiple therapeutic areas. With clinical training in both child and adult psychology and psychiatry, Dr. Halperin Wernli brings deep therapeutic expertise in neuroscience, psychiatry, women’s health, and rare diseases. As a seasoned pharmaceutical executive, she has extensive experience in drug development, regulatory affairs, project and portfolio management, development finance, and corporate strategy and governance.